ChemoCentryx (CCXI) PT Raised to $70 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq futures slide as Alphabet results intensify AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mail
Get Alerts CCXI Hot Sheet
Price: $10.25 --0%
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 21 | New: 16
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 21 | New: 16
Join SI Premium – FREE
Piper Sandler analyst Edward Tenthoff raised the price target on ChemoCentryx (NASDAQ: CCXI) to $70.00 (from $54.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agility Robotics expands Digit robot customer base ahead of Nasdaq listing
- C.H. Robinson Worldwide (CHRW) PT Lowered to $204 at UBS
- Agility Robotics Highlights Commercial Momentum and Growing Enterprise Demand for Digit Humanoid Robot
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
